@entity3724 is a member of the fibrate class of hypolipidemic agents used clinically to treat @entity2298 and mixed @entity407 . The fibrates were developed primarily on the basis of their @entity165 and @entity412 lowering in rodents. Fibrates have historically been ineffective at lowering @entity1674 in experimentally-induced @entity2299 in nonhuman primate models. The spontaneously @entity28 @entity2608 is a well-recognized animal model for the study of @entity1 @entity28 and @entity164 2 @entity6 , and many of these monkeys exhibit naturally occurring @entity14822 , including elevated @entity1674 and low HDL @entity165 (HDL-C), similar to @entity1 with @entity164 2 @entity6 . To explore whether the @entity28 rhesus model was predictive of the lipid lowering effects of fibrates, we evaluated @entity3724 in six @entity6308 , @entity1717 , nondiabetic animals in a 20-week, dose-escalating study. The study consisted of a 4-week baseline period, two treatment periods of 10 mg/kg twice daily (b.i.d) for 4 weeks and 30 mg/kg b.i.d. for 8 weeks, and a 4-week washout period. @entity3724 (30 mg/kg b.i.d) decreased serum @entity1674 55% and LDL-C 27%, whereas HDL-C increased 35%. Apolipoproteins B-100 and C-III levels were also reduced 70% and 29%, respectively. Food intake, body weight, and plasma @entity413 were not affected throughout the study. Interestingly, plasma insulin levels decreased 40% during the 30 mg/kg treatment period, suggesting improvement in insulin sensitivity. These results support the use of @entity28 @entity2608 as an excellent animal model for studying the effects of novel hypolipidemic agents, particularly agents that impact serum @entity1674 and HDL-C.

Effects of @entity3724 on lipid parameters in @entity28 XXXX .

@entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia'] @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia'] @entity3724 :: ('MESH:D011345', 'Chemical') :: ['fenofibrate', 'Fenofibrate'] @entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity14822 :: ('MESH:C562935', 'Disease') :: ['lipid abnormalities'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity6308 :: ('MESH:D064250', 'Disease') :: ['hypertriglyceridemic'] @entity1717 :: ('MESH:D044903', 'Disease') :: ['hyperinsulinemic'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity2608 :: ('9544', 'Species') :: ['rhesus monkey'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity2608 :: (9544,Species) :: ['rhesus monkeys']
